Evaluation of a passive hemagglutination assay as screening test and of a recombinant immunoblot as confirmatory test for serological diagnosis of Lyme disease

1994 ◽  
Vol 13 (7) ◽  
pp. 572-575 ◽  
Author(s):  
A. Hamann-Brand ◽  
M. Flondor ◽  
V. Brade
Keyword(s):  
Lyme Disease ◽  
Screening Test ◽  
Serological Diagnosis ◽  
Confirmatory Test ◽  
Hemagglutination Assay ◽  
Passive Hemagglutination

scholarly journals Immunoreactivity of Polish Lyme Disease Patient Sera to Specific Borrelia Antigens—Part 1

Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 2157
Author(s):  
Iwona Wojciechowska-Koszko ◽  
Magdalena Mnichowska-Polanowska ◽  
Paweł Kwiatkowski ◽  
Paulina Roszkowska ◽  
Monika Sienkiewicz ◽  
...  
Keyword(s):  
Lyme Disease ◽  
Clinical Picture ◽  
Screening Test ◽  
Disease Patient ◽  
Healthy People ◽  
Serological Diagnosis ◽  
Elisa Assay ◽  
Igg Antibodies ◽  
Igm Antibodies ◽  
Positive Results

The diverse clinical picture and the non-specificity of symptoms in Lyme disease (LD) require the implementation of effective diagnostics, which should take into account the heterogeneity of Borrelia antigens. According to available guidelines, laboratories should use a two-tier serological diagnosis based on the enzyme-linked immunosorbent (ELISA) screening test and confirmation of the immunoblot (IB). The aim of the study was to investigate the immunoreactivity of LD patient sera to Borrelia antigens and to attempt to identify the genospecies responsible for LD using an ELISA–IB assay combination. Eighty patients with suspected LD and 22 healthy people participated in the study. All samples were tested with ELISA and IB assays in both IgM and IgG antibodies. In the case of the ELISA assay, more positive results were obtained in the IgM class than in the IgG class. In the case of the IB assay, positive results dominated in the IgG class. Positive results obtained in the IB assay most often showed IgM antibodies against the OspC and flagellin antigens, whereas the IgG antibodies were against VlsE, BmpA, OspC, p41, and p83 antigens. The IB assay is an important part of LD serodiagnosis and should be mandatory in diagnostic laboratories.

scholarly journals Application of the Fluorescence Polarization Assay for Detection of Caprine Antibodies to Brucella melitensis in Areas of High Prevalence and Widespread Vaccination

2007 ◽  
Vol 14 (3) ◽  
pp. 299-303 ◽  
Author(s):  
C. Ramírez-Pfeiffer ◽  
K. Nielsen ◽  
P. Smith ◽  
F. Marín-Ricalde ◽  
C. Rodríguez-Padilla ◽  
...  
Keyword(s):  
Fluorescence Polarization ◽  
Screening Test ◽  
Brucella Melitensis ◽  
Low Cost ◽  
Animal Health ◽  
Screening Tests ◽  
Confirmatory Test ◽  
High Prevalence ◽  
Fluorescence Polarization Assay ◽  
World Organization

ABSTRACT The screening Rose Bengal test (RBT), the buffered plate agglutination test (BPAT), and the confirmatory complement fixation test (CFT) are currently approved by the World Organization for Animal Health (OIE) for diagnosis of goat brucellosis. However, RBT (at 3% or 8% cell concentration) is known to be affected by vaccinal antibodies. In the present study, Mexican and Canadian OIE tests were compared with the fluorescence polarization assay (FPA), alone or in combination, using indirect and competitive enzyme-linked immunosorbent assays as classification variables for goat sera obtained from an area of high prevalence and widespread vaccination. The relative sensitivities and specificities were, respectively, 99.7% and 32.5% for RBT3, 92.8% and 68.8% for RBT8, 98.4% and 84.8% for Canadian CFT, 83.7% and 65.5% for Mexican CFT, and 78.1% and 89.3% for FPA. The use of FPA as the confirmatory test in combination with other tests significantly increased the final specificities of the screening tests alone; BPAT, RBT3, and RBT8 plus FPA resulted in final specificities of 90%, 91.2%, and 91.3%, respectively, whereas for the combinations RBT3 plus Mexican CFT, RBT8 plus Mexican CFT, and BPAT plus Canadian CFT, specificities were 65.5%, 63.2%, and 91.7%, respectively. We suggest that FPA may be routinely applied as an adaptable screening test for diagnosis of goat brucellosis and as a confirmatory test for screening test series. Some advantages of FPA are that its cutoff can be adjusted to improve its sensitivity or specificity, it is a low-cost and easy-to-perform test of choice when specificity is relevant or when an alternative confirmatory test is not available, and it is not affected by vaccination, thus reducing the number of misdiagnosed and killed goats.

scholarly journals Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease

2018 ◽  
Vol 4 (4) ◽  
pp. 41 ◽  
Author(s):  
Shu-Chuan Chiang ◽  
Pin-Wen Chen ◽  
Wuh-Liang Hwu ◽  
An-Ju Lee ◽  
Li-Chu Chen ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Tandem Mass Spectrometry ◽  
Newborn Screening ◽  
Pompe Disease ◽  
Screening Test ◽  
Disease Screening ◽  
Confirmatory Test ◽  
Tandem Mass ◽  
Lysosomal Storage ◽  
Second Tier

Early diagnosis of lysosomal storage diseases (LSDs) through newborn screening (NBS) has been adapted widely. The National Taiwan University Hospital Newborn Screening Center launched the four-plex tandem mass spectrometry LSD newborn screening test in 2015. The test determined activities of acid α-glucosidase (GAA; Pompe), acid α-galactosidase (GLA; Fabry), acid β-glucocerebrosidase (ABG; Gaucher), and acid α-l-iduronidase (IDUA; MPS-I) in dried blood spots (DBS). Through 2017, 64,148 newborns were screened for these four LSDs. The screening algorithm includes enzyme activity/ratio as the cutoffs for the first screening test and a second-tier test for Pompe disease screening. The second-tier Pompe disease screening test measured activity inhibition by acarbose. Twenty-nine newborns required a confirmatory test; six were confirmed to have Pompe disease, and nine were confirmed to have Fabry disease. The screen-positive rate for Pompe disease was 0.031%. Therefore, in Pompe disease newborn screening, a validated 2nd tier test is necessary to decrease false positives.

scholarly journals Establishment of passive hemagglutination assay (PHA) system for anti-HBc in plasma.

1986 ◽  
Vol 149 (1) ◽  
pp. 11-20 ◽  
Author(s):  
YAHIRO UEMURA ◽  
KAZUMI FUKUYAMA ◽  
MASAYUKI NISHIDA ◽  
TADAKAZU SUYAMA ◽  
HITOSHI OHORI
Keyword(s):  
Hemagglutination Assay ◽  
Passive Hemagglutination

scholarly journals One-point method for serological diagnosis of leptospirosis: a microcapsule agglutination test

1987 ◽  
Vol 99 (2) ◽  
pp. 399-405 ◽  
Author(s):  
M. Seki ◽  
T. Sato ◽  
Y. Arimitsu ◽  
T. Matuhasi ◽  
S. Kobayashi
Keyword(s):  
Early Diagnosis ◽  
Screening Test ◽  
Agglutination Test ◽  
Point Method ◽  
Serological Diagnosis ◽  
Early Stages

SUMMARYThis paper describes a simple and rapid microcapsule agglutination (MCA) test. The results obtained by this new test have been compared with those obtained by the microtitre MCA and the microscopic agglutination (MA) test. The procedures required for the new test are easier and can be performed more rapidly than those necessary for the microtitre MCA test. Furthermore, the new test is more sensitive than the MA test in the early stages of leptospirosis.This new test appears satisfactory as a screening test for the early diagnosis of leptospirosis.

scholarly journals Assessment of a screening test to identify Lyme disease risk

2014 ◽  
Vol 40 (5) ◽  
pp. 83-87 ◽  
Author(s):  
NH Ogden ◽  
JK Koffi ◽  
LR Lindsay
Keyword(s):  
Lyme Disease ◽  
Screening Test ◽  
Disease Risk ◽  
Lyme Disease Risk
Sign in / Sign up

Export Citation Format

Share Document